LED Therapy for Oral Mucositis Prevention
Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation
Recruiting
N/A
Interventional Study
Myeloablative Allogeneic Hematopoietic Cell Transplantation
Intraoral Photobiomodulation Therapy
Oral Mucositis
Mucosal Ulcer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Supportive Care
- Participants needed
- 20 (estimated)
- Sponsor
- Dana-Farber Cancer Institute · Other
Who this trial is looking for
This trial is looking for adults who are scheduled to undergo a specific type of blood cell transplant. Participants will receive daily light therapy in their mouth to help prevent painful mouth sores during treatment.
Are You a Good Fit for This Trial?
You may be able to join if
- I am planned to undergo myeloablative allogeneic HCT.
- I am 18 years or older.
- I can understand the study information and sign a consent form.
You may not be able to join if
- I have had light therapy in my mouth within four weeks of my transplant admission.
- I have a history of radiation treatment to my head or neck.
- I have a history of photosensitivity.
- I am planned to receive palifermin for preventing mouth sores.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). Patients who are planned for alloHCT will receive daily intraoral photobiomodulation therapy (PBMT) using a novel LED device.
The name of the study device involved in this study is:
\- THOR L…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Planned to undergo myeloablative allogeneic HCT using FluBu4 conditioning and Tac-Mtx GVHD prophylaxis.
* Age ≥18 years.
* Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
* Participants who have had treatment with in…
Contacts